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Abstract
;-Irradiation–mediated ataxia telangiectasia mutated
(ATM)-dependent dephosphorylation of serine 376
(S376) at the carboxyl terminus of human p53 results in
the exposure of the 14-3-3 consensus-binding site,
which includes serine 378 (S378). 14-3-3 binding poten-
tiates p53’s DNA-binding ability and causes G1 arrest.
Moreover,endoplasmicreticulumstress–mediatedS376
phosphorylationwas shown to localizehumanp53 in the
cytoplasm. Although many functions are conserved be-
tweenhumanandmousep53, the functional relevanceof
S376 andS378mouse equivalents is not clear.We report
here that ;-irradiation does not lead to 14-3-3 binding to
mouse p53. Mouse p53 mutants, such as S373A/D (the
equivalent of human S376), S375A/D (the equivalent
of human S378), and combinatorial double mutants,
were not impaired in their ability to transactivate p53-
dependent target genes andwere capable of inducingG1
arrest as efficiently as wild-type p53. Consistently, all
mutant p53s were as potent as wild-type mouse p53 in
inhibitingcellular colony formation.Furthermore,mouse
S373A/D mutants were not defective in cytoplasmic lo-
calization in response to endoplasmic reticulum stress.
Together, the data suggest that despite a high ho-
mology with human p53, neither phosphorylation status
at S373 and S375 nor 14-3-3 binding may be a critical
event for mouse p53 to be functional.
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Introduction
p53 plays a central role in transmitting signals that regulate
cellular survival, proliferation, differentiation, and DNA re-
pair [1,2]. Optimal p53 function is achieved by several post-
translational modifications, especially on the amino and
carboxyl termini of the protein, which include phosphoryla-
tion, acetylation, sumolyation, and neddylation [3,4]. These
posttranslational modifications stabilize and recompartmen-
talize p53, resulting in both transcription-dependent and
transcription-independent regulations of various cellular
functions [5].
One such modification is the phosphorylation/dephos-
phorylation of serine 376 (S376) and serine 378 (S378) of
human p53. It has been shown that g-irradiation causes ataxia
telangiectasia mutated (ATM)-dependent dephosphorylation
at S376, generating a binding site for 14-3-3, which includes
phosphorylated S378, thereby increasing the DNA-binding
ability of p53 [6]. Subsequent studies showed that mutating
these binding sites impaired the ability of p53 to induce G1 cell-
cycle arrest [7]. However, S376 was shown to be phosphory-
lated by GSK-3b during endoplasmic reticulum (ER) stress
response, which led to cyctoplasmic sequestration of human
p53, thereby reducing the sensitivity of cells to other genotoxic
stresses [8]. Moreover, phosphorylation of human p53 at S378
by the CDK7–cycH–p36 complex or by protein kinase C was
shown to augment DNA-binding activity [9,10]. Hitherto, it has
not been established whether such modifications on the mouse
equivalents of S376 and S378 are required for efficient activa-
tion of mouse p53, although evidence points to the conserva-
tion of many posttranslational modifications between mouse
and human p53 [11–13].
We have therefore investigated the functional relevance of
S376 and S378 mouse equivalent sites in this study. The data
presented here suggest that despite a high homology with human
p53, neither phosphorylation status at S373 and S375 nor 14-3-3
binding may be a critical event for mouse p53 to be functional.
Materials and Methods
Cell Culture and Plasmids
The p53-null H1299 human lung cancer cell line, the human
breast carcinoma cell line MCF-7, human diploid fibroblasts
IMR90 and MRC5 (ATCC, Manassas, VA), and p53/ mouse
embryo fibroblasts (MEFs) were used in this study. All cell lines
were cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum (Hyclone, Logan, UT) in the
presence of 5% CO2 at 37jC, as described [14].
Transfections were carried out using Lipofectamine Plus
reagent (Invitrogen, Carlsbad, CA) as per the manufacturer’s
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description, generally using 5 mg of various p53 plasmids
(unless otherwise stated). Fifteen hours after transfection,
cells were g-irradiated with 10 to 20 Gy and harvested 3 hours
later for lysate preparation.
The S373 and S375 residues of mouse p53 were mutated
to nonphosphorylatable alanine (A) residues or aspartic acid
(D) that mimics phosphorylated residues by polymerase
chain reaction (PCR)–based site-directed mutagenesis.
PCR amplification was performed using pcDNA-based wild-
type mouse p53 expression construct as template, primers
carrying desired mutation, and Pfu polymerase (Promega,
Madison, WI). PCR products were digested with DpnI re-
striction enzyme (New England Biolabs, Ipswich, MA) before
transformation. Mutants were confirmed by restriction en-
zyme mapping and sequencing. Wild-type and mutant mouse
p53 cDNA in pcDNA-based constructs were released by
EcoRI (New England Biolaboratories) and subcloned into
pBabe retroviral vector [15]. All plasmids were sequenced
for verification. Green fluorescent protein (GFP)–encoding
plasmid pRNAT-U6.1/Hygro (Genescript; GenScript Corp.,
Piscataway, NJ) was used for cotransfection to evaluate
transfection efficiency in Western blot analysis. Human wild-
type or phosphomutant p53 IND constructs were kindly pro-
vided by Dr. Thanos Halozenetis.
Colony Formation Assays
p53/ MEFs were cotransfected with various pcDNA-
based p53 constructs and pLoxPuro plasmid [16] at a 10:1
ratio. Cells were selected with 2 mg/ml puromycin (Sigma,
St. Louis, MO) for 10 to 15 days and stained with crystal
violet (Sigma).
Luciferase Assays
Various p53 plasmids (0.5 mg) and luciferase reporter
plasmids (0.5 mg each) were cotransfected with 0.1 mg of
plasmid encoding the -galactosidase gene to evaluate
transfection efficiency. The following pGL3 basic vector–
based promoter reporter constructs were used in this study:
p21-luc andmdm2-luc. Cells were generally collected 48 hours
posttransfection, and luciferase assays were performed as
described [17]. All experiments were performed in duplicate,
and at least three independent times and representative re-
sults are shown.
Western Blot and Immunoprecipitation Analyses
Coimmunoprecipitation was performed using 1 mg of pro-
tein of whole-cell lysate with anti–14-3-3 antibody (K19)–
conjugated agarose beads (Santa Cruz Biotechnology,
Santa Cruz, CA), as described previously [7]. Immunopre-
cipitates and 50 mg of whole-cell lysate were resolved by 10%
SDS-PAGE and analyzed by Western blot analysis using the
following antibodies: anti–p53 Pab240 and Pab421 (Onco-
gene, San Diego, CA), anti–DO-1 (Oncogene), anti-CM5
(Novocastra, Newcastle, England, UK), anti–14-3-3 K19
(Santa Cruz Biotechnology), anti-actin (Santa Cruz Biotech-
nology), and anti-GFP (Santa Cruz Biotechnology). Blots
were detected using the ECLWestern blot detection reagent
(Amersham Biosciences, Buckinghamshire, England, UK).
RNA and Semiquantitative Reverse Transcription PCR
Total RNA was extracted from cultured cell lines using
Trizol reagent (Invitrogen), as per the manufacturer’s instruc-
tions, 24 hours after transfection. Total RNA was reverse-
transcribed to first-strand cDNA, 1 ml of which was used as a
template for quantitative PCR, subsequent to the optimiza-
tion of the number of PCR cycles, annealing temperature,
and extension time for each gene. The expression of endog-
enous p53 target genes (bax, noxa, mdm2, and p21) was
determined by semiquantitative reverse transcription (RT)
PCR and normalized against endogenous gaphd RNA level,
as described previously [18].
Flow Cytometric Analyses
Asynchronous p53/MEFs were transfected with 5 mg of
empty vector, wild-type p53 constructs, or phosphomutant
p53 constructs, and were later g-irradiated with 20 Gy. Simul-
taneous staining of intracellular p53 (with Pab246 primary
antibody and fluorescein isothiocyanate–conjugated anti–
mouse IgG antibody) and genomic DNA (by propidium
iodide) was performed as described [19], and the cells
were analyzed by flow cytometry with FACSCaliber (BD
Biosciences, Franklin Lakes, NJ). p53-expressing cells,
which emitted green fluorescence, were gated (except for
vector-transfected controls), and their cell-cycle profile was
determined by ModFIT cell-cycle analysis software (BD
Biosciences). All experiments were performed in duplicate
and at least twice independently.
Endoplasmic Stress Experiments
Cells were transfected with empty vector or p53-expressing
plasmids. Fifteen hours after transfection, cells were treated
with vehicle (DMSO), 10 mg/ml tunicamycin (TM), or 1 mM
thapsigargin (TG) for 8 hours to induce ER stress as de-
scribed [8]; fixed in 4% paraformaldehyde; and stained with
anti-p53 Pab240 or Pab1620 antibodies (Oncogene), followed
by Alexa488-conjugated anti–mouse IgG antibody (Molecular
Probes, Eugene, OR) and propidium iodide. Fluorescence
confocal microscopy was performed with an LSM 510 laser
scanning confocal microscope (Zeiss, Jena, Germany).
Results
Mouse p53, Unlike Human p53, Does Not Bind to 14-3-3
Initial experiments were performed to evaluate the phys-
ical interaction of mouse p53 and 14-3-3 by coimmunopre-
cipitation assays. Mouse or human p53 cDNA was transiently
transfected into either p53-null MEFs or human H1299 cells,
respectively. Total cell lysates were used to immunoprecipitate
14-3-3, which was followed by immunoblotting with anti-p53 or
anti–14-3-3 antibodies. Although human p53 was found to
bind endogenous 14-3-3, mouse p53 was unable to pull down
14-3-3 in the same experiments, although 14-3-3 was abun-
dantly expressed in mouse cell extracts (Figure 1A, left panel;
compare lane 1 vs lane 2, and lane 3 vs lane 4). Both p53s
were efficiently expressed in the cells, as determined by the
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immunoblotting of total cell lysates with anti-p53 antibodies
(Figure 1A, left panel, lanes 6 and 8), ruling out lack of mouse
p53 expression as a cause for the absence of 14-3-3 bind-
ing. It is noteworthy that the signal for mouse p53 was much
weaker than that for human p53. As this could be due to the
use of amixture of Pab240 and DO-1 antibodies to detect both
human and mouse p53 on the same blot, we reperformed this
experiment using the antibodies separately and detected the
blots individually. Similar to earlier results, human p53 was
again found to bind endogenous 14-3-3, whereas mouse p53
was unable to pull down 14-3-3 in the same experiments,
although 14-3-3 was abundantly expressed in mouse cell
extracts (Figure 1A, right panel; compare lane 1 vs lane 2,
and lane 3 vs lane 4). Both p53s were efficiently expressed in
the cells, as determined by the immunoblotting of total cell
lysates with anti-p53 antibodies (Figure 1A, right panel, lanes
5 and 6), ruling out lack of mouse p53 expression as a cause
for the absence of 14-3-3 binding.
We further tested whether endogenous mouse p53 could
bind to 14-3-3 after g-irradiation. As shown in Figure 1B,
Figure 1. Mouse p53 does not bind 14-3-3. (A) Empty pcDNA vector and wild-type human or mouse p53 were transfected into H1299 or p53/ MEFs,
respectively. Whole-cell lysates were immunoprecipitated with anti –14-3-3 antibody and analyzed by Western blot analysis using a mixture of Pab240 and DO-1
antibodies (left panel) or using these antibodies separately (right panel; Pab240 for mouse p53, and Pab421 for human p53) to detect p53 and K19 antibodies,
which, in turn, detect 14-3-3. (B) Human MCF-7 and primary MEFs were c-irradiated and collected after 3 hours, and 14-3-3 proteins were immunoprecipitated
for Western blot analysis as described in (A), using Pab421 and Pab240 to detect p53. (C) Human diploid fibroblast cells IMR90 and MRC5 were c-irradiated with
10 Gy, and the association of p53 with 14-3-3 was analyzed as described in (A), using DO-1 to detect human p53. All immunoprecipitation experiments have been
repeated three times or more. (D) Western blot analysis of the phosphorylation status of mouse p53. Wild-type primary MEFs cells were c-irradiated with 10 Gy and
harvested at various time points as indicated. The phosphorylation state of p53 was analyzed with Pab421 antibody, the total amount of p53 was determined by
CM5 antibody, and actin was used as loading control. Right panel: Blot with equal p53 protein loaded.
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whereas endogenous human p53 was coimmunoprecipitated
with endogenous 14-3-3 on g-irradiation in human MCF-7
cells, endogenous mouse p53 was not bound to 14-3-3 in
mouse fibroblasts (Figure 1B, compare lanes 1 and 2 vs
lanes 3 and 4). Nevertheless, p53 levels were induced by
g-irradiation in both cell types (Figure 1B, compare lane 5 vs
lane 6, and lane 7 vs lane 8), indicating that mouse p53 was
indeed induced by g-irradiation and may be different from
human p53 with respect to 14-3-3 binding.
Furthermore, the binding of p53 and 14-3-3 was also in-
creased on g-irradiation in the two human diploid fibroblastic
lines IMR90 andMRC5, ruling out differences betweenmouse
and human cell types as a cause for the lack of interaction in
mouse fibroblasts (Figure 1C). Moreover, immunoreactivity to
the Pab421 p53–specific antibody, which has a higher affinity
for dephosphorylated S376 (mouse 373) residue, increased
after g-irradiation in primary MEFs (Figure 1D), as has been
reported for human cells [6], suggesting that lack of 14-3-3
binding may not be due to the absence of change in the phos-
phorylation status of mouse p53 protein.
Characterization of Mouse Carboxyl-Terminal
Phosphorylation Mutants
Because the 14-3-3 binding of human p53 through de-
phosphorylated S376 and phosphorylated S378 was shown
to be required for p53 biologic activity [7], we investigated
the significance of equivalent sites in mouse p53. To this end,
mouse equivalents of human S375 and S378 were identified
by comparing the protein sequence homology between the
two species. The C-terminus of p53 is highly conserved, and
S373 and S375 residues of mouse p53 were identified as
human equivalents (Figure 2A). Then mouse p53 cDNA was
cloned into two different expression vectors, driven by either
the long terminal repeat of a retrovirus (pBabe) or the CMV
promoter (pcDNA), and site-directed mutagenesis was per-
formed to generate nonphosphorylatable alanine (A) mu-
tants and pseudophosphorylated aspartic acid (D) mutants.
The steady-state protein levels of all mutants generated
were approximately equal in both pBabe-based and pcDNA-
based constructs, suggesting that the phosphorylation state of
these two residues does not affect the stability of the protein
(Figure 2B). All subsequent experiments described were per-
formed with p53 mutants based on both types of vectors,
which showed similar and consistent results.
Using these constructs, we next evaluated the transacti-
vation potential of all mouse phosphomutants by transiently
transfecting them with themdm2 promoter-luciferase reporter
construct. The transactivation ability of all p53 phospho-
mutants was not significantly different from that of wild-
type mouse p53 without and with g-irradiation (Figure 2, C
and D). Similar results were obtained with a synthetic multi-
merized p53-responsive element containing a luciferase
reporter construct (PG13-luciferase; data not shown). Con-
sistently, semiquantitative RT-PCR analysis indicted that all
mouse phosphomutants were able to induce various endog-
enous p53 target genes, including bax, noxa, mdm2, and
p21, to equal extents as wild-type p53 (Figure 2G). Concur-
rently, the transactivation ability of the corresponding human
S376A, S378A, and S376-8A p53 mutants was determined
by luciferase assay (Figure 2, E and F ) and semiquantita-
tive RT-PCR (Figure 2H ). The results also showed that the
transactivation ability of human p53 phosphomutants was
comparable to that of the wild-type protein when overex-
pressed in H1299 cells, similar to previous observations in-
dicating that both human and mouse p53 phosphomutants
are transactivation-competent.
Mouse p53 Phosphomutants Are Not Defective in the
Induction of Cell Cycle Arrest
Because the phosphorylation status of the S376 and
S378 residues of human p53 was shown to be important
for cell-cycle arrest induction on g-irradiation, we tested the
ability of various mouse p53 phosphomutants to induce cell-
cycle arrest by transiently transfecting p53/ MEFs with
various p53 plasmids and by irradiating them. The trans-
fected cells expressing p53 were monitored by flow cytom-
etric analysis using an antibody that recognizes p53, and
only p53+ cells were analyzed. Similar to wild-type mouse
p53, all phosphomutants were capable of inducing G1 arrest
without g-irradiation, suggesting that all phosphomutants
are functionally active (the G1 population of pcDNA versus
WTp53-transfected cells: 40.81% vs 81.50%; all mutants
were in a similar range) (Figure 3A, top panel ). Consis-
tent with previous findings, p53-null cells failed to arrest at
G1 on g-irradiation, which led to a transient accumulation of
cells in G2/M phase (at 24 hours) (Figure 3A, middle panel ).
Subsequently, the cells re-entered the cell cycle, thereby
resulting in an increase in polyploid 8N populations 48 hours
Figure 2. Steady-state level and transactivation ability of mouse p53 phosphomutants. (A) The alignment of the C-termini of human (accession no. NP_000537)
and mouse (accession no. NP_035770) p53 proteins was performed by the Web-based alignment program BLAST2 (National Center for Biotechnology
Information). Conserved residues are shown in the middle row between human and mouse p53 sequences. Serine residues at positions 375 and 378 for human
p53, and at positions 373 and 375 for mouse p53, are indicated by boxes. (B) The S373 and S375 residues of mouse p53 were mutated to nonphosphorylatable
alanine (A) residues or aspartic acid (D) that mimics phosphorylated residues, and were expressed in pCDNA or pBabe vectors. p53/ MEFs were cotransfected
with 1 g of empty vector, wild-type or mutant mouse p53, and 0.2 g of GFP-encoding plasmids, and the steady-state level of p53 phosphomutants was
determined by Western blot analysis. (C) The transcriptional activity of the mouse phosphomutants was determined by luciferase assays, using mdm2 promoter-
luciferase construct. Luciferase activity was determined by chemiluminescence and was normalized against -galactosidase activity. The experiment was
performed thrice independently. Data from one of the experiments, performed in duplicate, are presented as mean ± SD. (D) Relative luciferase activity using the
mdm2 promoter-luciferase construct was determined in mouse p53– transfected c-irradiated (10 Gy) p53/ MEFs, as described above. The experiment was
performed twice independently. Data from one of the experiments, performed in duplicate, are presented as mean ± SD. (E and F) Relative luciferase activity using
p21 (E) and mdm2 promoter-luciferase constructs (F) together with human wild-type or phosphomutant IND constructs in p53-null H1299 cells. Data from one of
the experiments, performed in duplicate, are presented as mean ± SD. (G and H) The expression of endogenous p53 target genes (bax, noxa, mdm2, and p21) in
vector-transfected and p53-transfected p53/ MEFs (G) or human H1299 cells (H) was determined by semiquantitative RT-PCR and normalized against
endogenous gapdh RNA level as described previously.
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after g-irradiation (Figure 3A, bottom panel, leftmost). How-
ever, wild-type p53-expressing cells were arrested at both G1
and G2/M phases, and the cells that escaped G1 block
were eventually arrested at G2/M phase 48 hours after g-
irradiation (Figure 3A). All phosphomutants analyzed were
capable of inducing both G1 and G2/M cell-cycle arrests as
efficiently as wild-type p53 (Figure 3A), suggesting that the
phosphorylation state of the S373 and S375 residues of
mouse p53 is not important for g-irradiation– induced cell-
cycle arrest.
Analysis of cell death, by measuring sub-G1 population in
the cell-cycle profile, revealed that g-irradiation caused a
slight increase in cell death in pcDNA-transfected cells, and
expression of wild-type p53 enhanced cell death in the ab-
sence and in the presence of g-irradiation (Figure 3B, pcDNA
versus WTp53-transfected cells: ()g-irradiation: 4.8 ±
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0.71% vs 14.5 ± 0.57%; (+)g-irradiation 8.95 ± 2.90% vs
19.4 ± 3.11%). Similar results were obtained with pBabe-
based vectors (data not shown). All the phosphomutants
tested were capable of inducing cell death with or without
g-irradiation as efficiently as wild-type p53, suggesting that
mutations of phosphorylation sites had no significant im-
pact on the mutants’ ability to induce cell death. These
findings were also confirmed in long-term survival (colony
formation) assays in p53/ MEFs. Similar to wild-type p53,
all phosphomutant p53s were capable of significantly sup-
pressing colony formation, compared to pcDNA-transfected
cultures (Figure 3C). Together, the data suggest that the
phosphorylation status of S373 and S375 may not be essen-
tial for the optimal function of mouse p53.
Mouse p53 Phosphomutants, Unlike Their Human
Counterparts, Are Capable of Responding to ER Stress
We finally evaluated the role of these phosphorylation
sites in the cytoplasmic sequestration of p53 on induction of
ER stress, which has been shown to be dependent on the
Figure 3. Mouse p53 phosphomutants are not defective in inducing cell-cycle arrest. (A) Asynchronous p53/ MEFs were transfected with 5 g of empty vector,
wild-type p53 constructs, or phosphomutant p53 constructs, and were c-irradiated at 20 Gy. Simultaneous staining of intracellular p53 (with Pab246 primary
antibody and fluorescein isothiocyanate–conjugated anti –mouse IgG antibody) and genomic DNA (by propidium iodide) was performed before analysis by flow
cytometry. p53-expressing cells, which emitted green fluorescence, were gated (except for vector-transfected controls), and their cell-cycle profile was determined
by ModFIT cell-cycle analysis software (BD Biosciences). (B) Cell death was analyzed by determining sub-G1 populations in cell-cycle analysis, as described in (A),
by flow cytometry. Cells treated with and without 20 Gy c-irradiation and harvested 24 hours after c-irradiation were analyzed. The experiment was performed thrice
independently. Data from three independent experiments are presented as mean ± SD. (C) p53/ MEFs were cotransfected with pcDNA-based constructs, and
cells were selected with 2 g/ml puromycin (Sigma) for 10 to 15 days and stained with crystal violet (Sigma). Colony formation assay was performed four
independent times, and representative data are shown.
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phosphorylation state of the S376 residue of human p53 [8].
To this end, p53/ MEFs were transfected with various
S373mouse mutant constructs and treated with ER-inducing
drugs such as TM or TG, and the localization of p53 was
determined by immunofluorescence using the Pab240 anti-
body. As shown in Figure 4A (upper panels), majority of the
transfected p53 localized to the nucleus of the cells, regard-
less of phosphomutations (Figure 4B, WTp53 vs 373A vs
373D: 76.54 ± 0.61% vs 76.03 ± 0.88% vs 75.20 ± 0.83%).
TM-mediated or TG-mediated ER stress resulted in a signif-
icant increase in the sequestration of wild-type mouse p53 in
the cytoplasm (Figure 4A, arrows; B, untreated versus TM
versus TG: 76.54 ± 0.61% vs 37.16 ± 7.75% vs 41.19 ±
1.68%). Both S373A and S373D phosphomutants were also
found to translocate efficiently to the cytoplasm on ER stress
(Figure 4, A and B). Similar results were obtained when anal-
ysis was performed using another anti-p53 antibody
(Pab1620; Figure 4C). Moreover, the phosphorylation status
of the S375 residue of mouse p53 was also found to be dis-
pensable for cytoplasmic sequestration (data not shown),
suggesting that the phosphorylation status of neither S373
nor S375 residue is important for p53 cytoplasmic localiza-
tion on ER stress. Conversely and as published previously,
S376A mutant human p53 failed to be exported from the
nucleus on ER stress, in contrast to wild-type human p53,
suggesting that the mechanisms of p53 nuclear export after
ER stress may be different between mouse and human cells
(Figure 4D).
Discussion
The results presented here suggest that mouse p53 is not
similar to human p53 in some aspects, as the former is un-
able to bind 14-3-3, and, consistently, the serine residues
that are thought to be required for the exposition of the 14-3-
3–binding motif on human p53 do not seem to be function-
ally relevant in mouse p53. Although both human and mouse
p53 are highly homologous in the carboxyl-terminal region of
the protein, none of the mouse p53 phosphomutants (either
A or D) was able to bind 14-3-3 (data not shown). These
findings suggest that the phosphorylation status of S376 and
S378 residues alone may not be sufficient for 14-3-3 binding
in human p53 and that other unidentified factors may influ-
ence this phenomenon.
It is known that 14-3-3 isoforms bind to proteins in both a
phosphorylation-dependent and a phosphorylation-independent
manner. In phosphorylation-dependent binding, it recognizes
RSXpSXP and RXXXpSXP epitopes, where pS represents
phosphoserine (can be interchanged with phosphothreonin)
and X represents any amino acid [20]. In the case of both
human and mouse p53, the 14-3-3–binding site is believed
to be KGQSTpSRH [6], in which arginine and proline res-
idues critical for 14-3-3 binding are not found. Therefore,
the site on p53 is not a perfect 14-3-3–binding motif and,
hence, may be a low-affinity binding site. Moreover, a pep-
tide containing two binding sites showed a 30-fold increased
affinity for 14-3-3 than peptides having a single binding
motif [20], consistent with the notion that 14-3-3 preferen-
tially binds to some targets as a dimer [21]. However, the
second putative 14-3-3–binding motif has not been identi-
fied in both human and mouse p53. Thus, it is not uncon-
ceivable that human p53 may only weakly bind to 14-3-3.
Therefore, in addition to the above characteristics and given
the substantial differences between human and mouse p53
in the amino acid sequence around this 14-3-3–binding site,
it is possible that mouse p53 is not a good binding target
for 14-3-3.
Moreover, the results prompt us to speculate that 14-3-3
binding to p53 may be an evolutionarily late event that oc-
curred with only human p53 (perhaps to optimize its func-
tion) and was not essential for efficient functioning of mouse
p53. In this respect, DNA damage–mediated interaction
between human p53 and 14-3-3 was shown to stabilize
p53, thereby facilitating oligomerization, blocking nuclear
export, and increasing the transactivation ability of p53,
in turn resulting in cell-cycle arrest [22,23]. However, all
mouse phosphomutants were not altered in their steady-
state levels or in their transactivation potential, further sug-
gesting that modifications of these phosphorylation sites may
not be crucial in regulating the function of the mouse pro-
tein. Furthermore, it is noteworthy that 14-3-3j is a target of
human p53 [22], suggesting the existence of a positive
feedback loop between human p53 and 14-3-3 protein [23].
However, data suggesting the existence of this feedback
loop in mouse cells are lacking, and mouse 14-3-3 appears
to be unresponsive to p53 (M. Resnick et al., personal
communication). Therefore, the data suggest that a positive
feedback loop may not exist in the mouse system because
we did not observe any binding of 14-3-3 to mouse p53
protein, thereby explaining the lack of any functional deficien-
cies of phosphomutant proteins. However, as both human
and mouse p53 have extremely similar functions, it is pos-
sible that the differences between them are functionally
irrelevant, or, alternatively, there has been convergent evolu-
tion where these two p53s perform similar functions through
different mechanisms.
Consistent with the lack of 14-3-3 binding, mouse p53
phophomutants were not defective in cell-cycle arrest or
apoptosis induction. In addition, phosphomutations had no
effect on the subcellular shuttling of mouse p53, in contrast to
human p53, on ER stress, which was shown to be dependent
on the phosphorylation of the S315 and S375 residues of
human p53 by GSK-3b in transient transfection assays [8].
However, unlike the absence of interaction between mouse
p53 and 14-3-3, we observed the binding of mouse p53 with
GSK-3b during ER stress in coimmunoprecipitation experi-
ments (data not shown), similar to that observed with human
p53, suggesting that this association may also be important
for the shuttling of mouse p53 on ER stress. Nevertheless,
the S373 residue of mouse p53 does not play a role in its
localization of mouse p53 and raises the possibility that the
S312 of mouse p53—which is the equivalent of S315, rather
than S373, in human p53—may be essential for ER stress–
mediated cytoplasmic shuttling.
This work was initiated to evaluate the functional signifi-
cance of the two carboxyl-terminal phosphorylation sites in
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Figure 4. Mouse p53 phosphomutants, unlike their human counterparts, respond to ER stress as efficiently as wild-type p53. (A) p53/ MEFs were transfected
with empty vector, wild-type mouse p53, or phosphomutant mouse p53, and then treated with vehicle (DMSO), 10 g/ml TM, or 1 M TG for 8 hours to induce ER
stress. Cells were fixed and stained with anti-p53 antibody and propidium iodide before fluorescence confocal microscopy. Representative images, in which green
fluorescence represents p53 protein and red fluorescence represents genomic DNA, are shown. Arrows indicate cells in which p53 is cytoplasmic. (B) Quantitative
analysis of cells having cytoplasmic p53. Approximately 500 p53-expressing cells were scored and classified into cells with or without nuclear p53 stain. Data from
one of the experiments, performed in triplicate, are presented as mean ± SD. (C) Similar experiments were carried out as described in (A) and (B) and were
analyzed using another anti-p53 antibody (Pab1620). (D) H1299 cells were transfected with empty vector, wild-type human p53, or phosphomutant human p53
(376A or 376–378A[3A]). ER stress was induced by 1 M TG, as described in (A). Approximately 500 p53-expressing cells were scored and classified into cells
with or without nuclear p53 stain. Data from one of the experiments, performed in triplicate, are presented as mean ± SD. All experiments were performed at least
thrice independently.
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mouse p53, which has not been performed before. We found
that g-irradiation of mouse cells led to the induction of a
band recognizable by Pab421, which recognizes human p53
that is dephosphorylated at the S376 residue, suggesting
that dephosphorylation of mouse S373 may also occur on
g-irradiation. It should be noted that this epitope could also
be regulated by other posttranslational modifications such as
ubiquitination and acetylation, although we are not aware of
any reports indicating that such modifications may affect
recognition by the antibody. However, this event cannot be
directly tested as the available anti-pS376 (human) antibody
does not recognize mouse p53 (data not shown). This study
was therefore undertaken to evaluate the significance of
these posttranslational modifications in cultured cells using
transient transfections before embarking on the generation
of ‘‘knock-in’’ mouse models to address the in vivo signifi-
cance of these phosphorylation sites. In this respect, it
should be noted that most experiments aimed at defining
the functional significance of human S376 and S378 were
also performed by transient transfection experiments [8,7],
suggesting that this system is sufficient to uncover any func-
tional deficiencies using phosphomutant constructs in a
short period of time. Being mindful of the high levels of pro-
teins expressed in these transient systems, we had gener-
ated two sets of constructs driven by different promoter
elements that result in either higher expression (pcDNA-
based constructs) or expression levels similar to physiolog-
ical settings (pBabe-based constructs), which gave similar
results. Similar strategies have been employed in other
studies aimed at understanding the physiological signifi-
cance of various posttranslational modifications before the
generation of knock-in mice, which is a time-consuming
process. For example, the effects of phosphorylation at the
S389 [11] and S18 [24] residues of mouse p53 were first in-
vestigated in cell culture models, and these findings were
eventually confirmed with the use of knock-in models [13,25].
Hence, cell culture models, as described here, can provide
useful clues for elucidating the significance of posttransla-
tional modifications before embarking on the generation of
modified mice.
In conclusion, we have tested the physiological relevance
of the S373 and S375 residues of mouse p53 and have
demonstrated that the phosphorylation status of these sites
is not relevant to the efficient functioning of mouse p53.
These data suggest that some of the posttranslational events
regulating p53 function may have been acquired later in
evolution, specifically for fine-tuning the regulation of essen-
tial properties in higher organisms.
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